Revealia™
The world’s most convenient cancer screen is about to hit the market. A simple mail-order cheek swab can help save lives.
mRNA Inflammatory Index™
Patent pending technology that combines gene sequencing microassay and artificial intelligence that measures and monitors 48 different biomarkers of chronic inflammation. Available in Q4 2023.
Precision Genomics™
Precision Genomics, Ludwig Enterprises’ subsidiary, supports the pharmaceutical, biotechnology and clinical research. Precision Genomics’s extensive patient meta data and mRNA microassay results could be of value during the drug and product development process. Precision Genomics is developing partnerships for clinical research with universities, clinical research organizations, health systems and healthcare providers.
Download FDA Presentation Precision Genomics
